Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

NCT02165202 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

136

Enrollment

OTHER

Sponsor class

Conditions

Human Immunodeficiency Virus (HIV)

Interventions

DRUG: Rilpivirine
DRUG: Placebo

Sponsor

PATH

Collaborators

[object Object]
[object Object]
[object Object]